Herbalife's third quarter split cleanly between the income statement's top and bottom lines. Adjusted EPS of $0.64 missed the $0.73 consensus by 15.8% and fell further short of the $0.76 Earnings Whisper number. Yet earnings still grew 28.0% year over year, and revenue of $1.35 billion beat consensus by 3.9% on 6.0% growth. The central tension is that the operating business is accelerating while the conversion of that growth into per-share earnings lagged what investors were modeling. A leadership shake-up and a more cautious margin message add a second layer of uncertainty.

The quality of the beat at the operating level is hard to dispute. Constant-currency sales rose 7.6%, up from 5.8% in Q2 and 5.4% in Q1, and cleared the top of management's own guidance range by roughly 210 basis points. That marked a fifth straight quarter of growth. Worldwide volume accelerated to +8.6%, from +5.8%, +4.1% and +3.1% over the prior three quarters, so this was not a pricing story. Adjusted EBITDA of $182.4 million topped the $160 million to $180 million guide, and margin expanded 70 basis points to 13.5%.

The EPS shortfall traces to items below that line:

• a $0.06 year-over-year FX hit;
• a heavy GAAP tax provision of $49.5 million on $106.6 million of pretax income;
• a diluted share count that rose to 107.3 million from 104.0 million.

The April refinancing helped, cutting net interest expense by $19.1 million, but not enough to close the gap to expectations. GAAP diluted EPS was $0.55.

Beneath the headline, the growth remains geographically narrow. Asia Pacific rose 26.1% in constant currency, with India up 52% in local currency, and Latin America added 5.1%. North America grew just 1.7%, although that is its second consecutive positive quarter after a 3% decline in Q1. EMEA fell 5.2% and China dropped 26.4%. Gross margin slipped 40 basis points to 77.3%, continuing a drift from 77.9% in Q1 and 77.7% in Q2, on mix and self-manufacturing costs. The EBITDA expansion therefore came from expense leverage, not product economics.

Guidance is where the story gets more complicated. Full-year reported sales growth was raised to 4.9% to 5.9%, the third straight increase. Constant-currency adjusted EBITDA moved up to $700 million to $720 million. However, reported EBITDA guidance was held at $670 million to $690 million because the FX headwind widens to roughly 200 basis points in Q4. Fourth-quarter EBITDA guidance of $145 million to $165 million implies a sequential margin step-down, and India begins lapping its GST benefit. New CFO Scott Schaefer cautioned that further margin expansion will be more gradual and that input costs are being watched for 2027. Bears have legitimate ammunition here: accelerating sales are not yet translating into a steeper earnings trajectory.

The leadership and strategy changes deserve as much attention as the numbers. CEO Stephan Gratziani has departed. John DeSimone, who had announced his retirement as CFO, is now interim CEO, and Schaefer moved into the CFO seat earlier than planned. Protocol, previously framed as a strategic centerpiece, was recast as a low-usage beta on a parallel path. Life.io was folded into Bionic, which has sold fewer than 50,000 units. The forward catalysts are real but mostly deferred:

• a modular customer engagement platform launching in Q1 2027;
• a dedicated nutrition-club organization, with club productivity up 10%;
• a GLP-1 companion program;
• three-year margin targets promised on the Q4 call.

The call drew only a single analyst question, leaving much of this unexamined.

Capital allocation shifted meaningfully. Net leverage reached 2.0x, hitting the year-end target a quarter early, and year-to-date operating cash flow rose 27% to $298.0 million. That allowed the board to authorize a $250 million, three-year buyback beginning in Q4. This is a notable pivot from the debt-paydown-only message of earlier quarters. Over time it could also counter the share creep that weighed on this quarter's EPS.

Investor sentiment became moderately more positive into the report, rising from 0.30 to 0.39. Shares were up 13.0% since the post-Q2 open at $13.05 as of the pre-report snapshot. Still, the stock sat 6.9% below its 200-day moving average and 12.3% below its mid-October high of $14.89, after rallying 25.4% off the late-August low. Momentum and AVWAP readings are positive while the price trend is neutral. That picture fits a market that was warming to the turnaround but had already pulled back from its highs before an EPS miss and a CEO exit.

The bottom line is that Herbalife delivered its strongest volume growth in at least four quarters, beat on sales and EBITDA, and raised full-year sales guidance. However, it missed on EPS, held reported EBITDA flat, signaled slower margin progress, and lost its CEO mid-transformation. The top-line turnaround looks increasingly credible; whether it becomes an earnings story now depends on a new leadership team and margin targets investors have not yet seen.